SS
GTBP icon

SBI Securities’s GT Biopharma GTBP Stock Holding History

SBI Securities’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
1
– – ﹤0.01% 4130
2026
Q1 		$0 Hold
1
– – ﹤0.01% 4084
2025
Q4 		$1 Sell
1
-4
-80% -$3 ﹤0.01% 3997
2025
Q3 		$3 Sell
5
-1
-17% -$1 ﹤0.01% 4132
2025
Q2 		$21 Sell
6
-2
-25% -$5 ﹤0.01% 3908
2025
Q1 		$17 Sell
8
-8
-50% -$19 ﹤0.01% 3886
2024
Q4 		$49 Buy
+16
New +$43 ﹤0.01% 3648

Other funds holding GTBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
KP
Kitching Partners Conshohocken, Pennsylvania $116M AUM 16.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

SBI Securities's GTBP Position: Q2 2026 in Review

SBI Securities held its GT Biopharma (GTBP) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4130.

SBI Securities first reported a position in GTBP in Q4 2024 and has held it in 7 quarters since. The position peaked at $49 in Q4 2024. 41 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • SBI Securities held 1 share of GT Biopharma worth $0 as of Q2 2026.
  • SBI Securities left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #4130 holding.
  • SBI Securities first reported a position in GT Biopharma in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's GT Biopharma position peaked at $49 in Q4 2024.
  • 41 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.